CG Oncology (CGON) Cash from Investing Activities (2023 - 2026)

CG Oncology (CGON) has 4 years of Cash from Investing Activities data on file, last reported at -$334.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 79.28% year-over-year to -$334.8 million; the trailing twelve-month figure through Mar 2026 stood at -$393.9 million (down 118.72% YoY), and the FY2025 full-year result was -$245.8 million, up 18.27% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$334.8 million, down from -$75.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $103.4 million in Q2 2023 and bottomed at -$334.8 million in Q1 2026.
• The 4-year median for Cash from Investing Activities is -$36.2 million (2024), against an average of -$77.1 million.
• The widest annual swing landed in 2024, when Cash from Investing Activities soared 119.83%; it then slumped 792.39% in 2025.
• A 4-year view of Cash from Investing Activities shows it stood at $15.5 million in 2023, then dropped by 29.8% to $10.9 million in 2024, then plunged by 792.39% to -$75.5 million in 2025, then plunged by 343.47% to -$334.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$334.8 million (Q1 2026), -$75.5 million (Q4 2025), and $15.0 million (Q3 2025), per Business Quant data.

Peer Comparison